J&J’s 2018 Remicade patent smacked down at PTO again

Tracy Staton

Johnson & Johnson said the U.S. and Trademark Office rejected a for the second time, putting the blockbuster anti-inflammatory's exclusivity in jeopardy. But the company also said it would appeal, a process that could take years.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS